Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Saved in:
| Title: | Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. |
|---|---|
| Authors: | Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK. thomas.powles1@nhs.net., Choueiri TK; Dana-Farber Cancer Center, Boston, MA, USA., Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jonasch E; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pal S; City of Hope National Medical Center, Duarte, CA, USA., Tannir NM; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Signoretti S; Brigham and Women's Hospital, Boston, MA, USA., Kaldate R; Exelixis, Inc, Alameda, CA, USA., Scheffold C; Exelixis, Inc, Alameda, CA, USA., Wang E; Exelixis, Inc, Alameda, CA, USA., Aftab DT; Exelixis, Inc, Alameda, CA, USA., Escudier B; Gustave-Roussy, Villejuif, France., George DJ; Duke Cancer Institute, Durham, NC, USA. |
| Source: | BMC cancer [BMC Cancer] 2021 Aug 07; Vol. 21 (1), pp. 904. Date of Electronic Publication: 2021 Aug 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34364385 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Barts Cancer Institute, Queen Mary University of London, London, UK. thomas.powles1@nhs.net.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Dana-Farber Cancer Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Motzer+RJ%22">Motzer RJ</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Jonasch+E%22">Jonasch E</searchLink>; University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Pal+S%22">Pal S</searchLink>; City of Hope National Medical Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tannir+NM%22">Tannir NM</searchLink>; University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Signoretti+S%22">Signoretti S</searchLink>; Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kaldate+R%22">Kaldate R</searchLink>; Exelixis, Inc, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Scheffold+C%22">Scheffold C</searchLink>; Exelixis, Inc, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+E%22">Wang E</searchLink>; Exelixis, Inc, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Aftab+DT%22">Aftab DT</searchLink>; Exelixis, Inc, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Escudier+B%22">Escudier B</searchLink>; Gustave-Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22George+DJ%22">George DJ</searchLink>; Duke Cancer Institute, Durham, NC, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100967800%22">BMC cancer</searchLink> [BMC Cancer] 2021 Aug 07; Vol. 21 (1), pp. 904. <i>Date of Electronic Publication: </i>2021 Aug 07. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100967800 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-2407 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214712407%22">14712407 </searchLink><i>NLM ISO Abbreviation: </i>BMC Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34364385 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12885-021-08630-w Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 904 Titles: – TitleFull: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Powles T – PersonEntity: Name: NameFull: Choueiri TK – PersonEntity: Name: NameFull: Motzer RJ – PersonEntity: Name: NameFull: Jonasch E – PersonEntity: Name: NameFull: Pal S – PersonEntity: Name: NameFull: Tannir NM – PersonEntity: Name: NameFull: Signoretti S – PersonEntity: Name: NameFull: Kaldate R – PersonEntity: Name: NameFull: Scheffold C – PersonEntity: Name: NameFull: Wang E – PersonEntity: Name: NameFull: Aftab DT – PersonEntity: Name: NameFull: Escudier B – PersonEntity: Name: NameFull: George DJ IsPartOfRelationships: – BibEntity: Dates: – D: 07 M: 08 Text: 2021 Aug 07 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1471-2407 Numbering: – Type: volume Value: 21 – Type: issue Value: 1 Titles: – TitleFull: BMC cancer Type: main |
| ResultId | 1 |
